Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-04-05 DOI:10.2217/imt-2024-0031

Maodong Fu, Xiuping Zhang, Feng Shen, Jun Ma, Zhiyong Li

引用次数: 0

Abstract

Aim: The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) for predicting immunotherapy prognosis and efficacy in advanced gastric cancer (GC). Methods: A total of 84 advanced GC patients received immunotherapy were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, PIV and SII on patients prognosis. Results: NLR, PLR, PIV and SII had predictive value of efficacy. NLR ≥3.65 was an independent risk factor for worse outcomes. Conclusion: NLR, PLR, PIV and SII have predictive value of efficacy and NLR ≥3.65 suggests a poor prognosis following immunotherapy in advanced GC.

查看原文本刊更多论文

外周血中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值、泛免疫炎症值和全身免疫炎症指数对晚期胃癌患者免疫疗法疗效的预后价值

目的：本研究旨在评估治疗前外周血中性粒细胞/淋巴细胞比值（NLR）、血小板/淋巴细胞比值（PLR）、泛免疫炎症值（PIV）和全身免疫炎症指数（SII）对晚期胃癌（GC）免疫治疗预后和疗效的预测价值。研究方法回顾性收集了84例接受免疫治疗的晚期胃癌患者。通过接收者操作特征曲线确定最佳临界值。单变量和多变量分析研究了NLR、PLR、PIV和SII对患者预后的影响。结果如下NLR、PLR、PIV和SII对疗效有预测价值。NLR≥3.65是预后较差的独立风险因素。结论：NLR、PLR、PIV 和 SII 具有预测疗效的价值：NLR、PLR、PIV和SII对疗效有预测价值，NLR≥3.65提示晚期GC患者接受免疫治疗后预后较差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.